Artiva Biotherapeutics (NASDAQ:ARTV) Receives New Coverage from Analysts at Needham & Company LLC

Needham & Company LLC assumed coverage on shares of Artiva Biotherapeutics (NASDAQ:ARTV) in a research note published on Tuesday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $23.00 price target on the stock.

Artiva Biotherapeutics Price Performance

Shares of ARTV opened at $11.36 on Tuesday. Artiva Biotherapeutics has a 52-week low of $10.50 and a 52-week high of $16.00.

Insider Buying and Selling

In other news, Director Yong-Jun Huh bought 2,083,332 shares of the firm’s stock in a transaction on Monday, July 22nd. The shares were bought at an average cost of $12.00 per share, for a total transaction of $24,999,984.00. Following the acquisition, the director now directly owns 3,306,900 shares of the company’s stock, valued at approximately $39,682,800. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Artiva Biotherapeutics news, Director Yong-Jun Huh bought 2,083,332 shares of the business’s stock in a transaction on Monday, July 22nd. The stock was bought at an average price of $12.00 per share, with a total value of $24,999,984.00. Following the completion of the purchase, the director now directly owns 3,306,900 shares in the company, valued at $39,682,800. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Global Strategic Fund I. Venbio purchased 416,666 shares of the firm’s stock in a transaction dated Monday, July 22nd. The stock was acquired at an average cost of $12.00 per share, for a total transaction of $4,999,992.00. Following the purchase, the insider now owns 1,936,637 shares in the company, valued at $23,239,644. The disclosure for this purchase can be found here.

About Artiva Biotherapeutics

Artiva Biotherapeutics Inc is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. The company’s lead program includes AlloNK(R). Artiva Biotherapeutics Inc is based in SAN DIEGO.